Log in

CONMED Stock Forecast, Price & News

-1.41 (-1.74 %)
(As of 10/28/2020 12:00 AM ET)
Today's Range
Now: $79.43
50-Day Range
MA: $81.86
52-Week Range
Now: $79.43
Volume399,350 shs
Average Volume364,567 shs
Market Capitalization$2.27 billion
P/E Ratio83.61
Dividend Yield0.99%
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. It offers orthopedic surgery products under Hall, CONMED Linvatec, Concept, and Shutt brands. The company also offers general surgery product in the areas of advanced surgical comprising clinical insufflation system; electrosurgical products; and endomechanical products comprising instruments, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors. In addition, it offers endoscopic technologies offering, including diagnostic and therapeutic products for use in gastroenterology procedures; cardiology and critical care products cover a line of vital signs, cardiac monitoring, and patient care products, including ECG electrodes and accessories, cardiac defibrillation and pacing pads, and suction instruments and tubing; and physician's office electrosurgical product used by dermatologists. The company markets its products directly to surgeons, hospitals, surgery centers, group purchasing organizations, integrated delivery networks, and other customers, as well as through medical specialty distributors. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.6Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
Current SymbolNASDAQ:CNMD



Sales & Book Value

Annual Sales$955.10 million
Cash Flow$3.47 per share
Book Value$23.54 per share


Net Income$28.62 million


Market Cap$2.27 billion
Next Earnings DateN/A
-1.41 (-1.74 %)
(As of 10/28/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CNMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CNMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

CONMED (NASDAQ:CNMD) Frequently Asked Questions

How has CONMED's stock been impacted by COVID-19?

CONMED's stock was trading at $78.77 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CNMD shares have increased by 0.8% and is now trading at $79.43.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of CONMED?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for CONMED

How were CONMED's earnings last quarter?

CONMED Co. (NASDAQ:CNMD) issued its earnings results on Wednesday, October, 28th. The medical technology company reported $0.88 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.29 by $0.59. CONMED had a net margin of 3.00% and a return on equity of 11.18%.
View CONMED's earnings history

How often does CONMED pay dividends? What is the dividend yield for CONMED?

CONMED announced a quarterly dividend on Friday, August 14th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.20 per share on Monday, October 5th. This represents a $0.80 dividend on an annualized basis and a yield of 1.01%. The ex-dividend date is Monday, September 14th.
View CONMED's dividend history

What price target have analysts set for CNMD?

6 brokerages have issued 12-month price targets for CONMED's stock. Their forecasts range from $76.00 to $115.00. On average, they anticipate CONMED's stock price to reach $98.00 in the next year. This suggests a possible upside of 23.4% from the stock's current price.
View analysts' price targets for CONMED

Who are some of CONMED's key competitors?

What other stocks do shareholders of CONMED own?

Who are CONMED's key executives?

CONMED's management team includes the following people:
  • Mr. Curt R. Hartman, Chairman, CEO & Pres (Age 56, Pay $2.04M)
  • Mr. Todd W. Garner, Exec. VP & CFO (Age 51, Pay $941.04k)
  • Mr. Patrick J. Beyer, Pres of International & Global Orthopedics (Age 54, Pay $927.34k)
  • Mr. Stanley W. Peters III, VP & GM of U.S. Advanced Surgical (Age 45, Pay $858.66k)
  • Mr. Nathan Folkert, VP & GM of U.S. Orthopedics (Age 45, Pay $626.98k)

What is CONMED's stock symbol?

CONMED trades on the NASDAQ under the ticker symbol "CNMD."

Who are CONMED's major shareholders?

CONMED's stock is owned by a variety of retail and institutional investors. Top institutional investors include AMI Asset Management Corp (0.31%), Envestnet Asset Management Inc. (0.11%), State of Alaska Department of Revenue (0.09%), State of New Jersey Common Pension Fund D (0.09%), Louisiana State Employees Retirement System (0.05%) and Nisa Investment Advisors LLC (0.04%). Company insiders that own CONMED stock include Brian Concannon, Daniel Jonas, Dirk Kuyper, Heather L Cohen, John Jed Kennedy, John L Workman, Johonna Marie Pelletier, Peter K Shagory, Stanley W Peters III, Terence M Berge and Wilfredo Ruiz-Caban.
View institutional ownership trends for CONMED

Which institutional investors are selling CONMED stock?

CNMD stock was sold by a variety of institutional investors in the last quarter, including AMI Asset Management Corp, State of New Jersey Common Pension Fund D, KBC Group NV, Envestnet Asset Management Inc., Crossmark Global Holdings Inc., and State of Alaska Department of Revenue. Company insiders that have sold CONMED company stock in the last year include Brian Concannon, Daniel Jonas, John Jed Kennedy, Peter K Shagory, Stanley W Peters III, and Wilfredo Ruiz-Caban.
View insider buying and selling activity for CONMED

Which institutional investors are buying CONMED stock?

CNMD stock was acquired by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System, Integrated Investment Consultants LLC, Wendell David Associates Inc., First Bank & Trust, Nisa Investment Advisors LLC, and Harbor Investment Advisory LLC. Company insiders that have bought CONMED stock in the last two years include Heather L Cohen, and John L Workman.
View insider buying and selling activity for CONMED

How do I buy shares of CONMED?

Shares of CNMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CONMED's stock price today?

One share of CNMD stock can currently be purchased for approximately $79.43.

How big of a company is CONMED?

CONMED has a market capitalization of $2.27 billion and generates $955.10 million in revenue each year. The medical technology company earns $28.62 million in net income (profit) each year or $2.64 on an earnings per share basis. CONMED employs 3,300 workers across the globe.

What is CONMED's official website?

The official website for CONMED is www.conmed.com.

How can I contact CONMED?

CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The medical technology company can be reached via phone at 315-797-8375.

This page was last updated on 10/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.